investorscraft@gmail.com

Aurinia Pharmaceuticals Inc. (AUPH)

Previous Close
$7.59
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)65.12758
Intrinsic value (DCF)169.942139
Graham-Dodd Method2.84-63
Graham Formula1.64-78

Company Information

4464 Markham Street
Edmonton, BC V8Z 7X8
Canada
Phone: 12507084272
Industry: Biotechnology
Sector: Healthcare
CEO: Mr. Peter S. Greenleaf M.B.A.
Full Time Employees: 130

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

HomeMenuAccount